Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.68 | -0.25
Decreased by
-172.00%
|
Aug 22, 22 | -0.52 | -0.42
Decreased by
-23.81%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-5.04 M
Decreased by
-685.70%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-4.66 M
Decreased by
-385.10%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00 - | -4.65 M - |
Decreased by
N/A%
-
|
Dec 31, 21 | 0.00 - | -4.97 M - |
Decreased by
N/A%
-
|
Sep 30, 21 | 0.00 - | 860.00 K - |
Increased by
+N/A%
-
|
Sep 30, 20 | 0.00 - | -960.00 K - |
Decreased by
N/A%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.